BlueChew AI Visibility Market Strategy Report - ED Treatment Pills

Answer Capsule

BlueChew holds a visible but under-recommended position in the October 2026 ED Treatment Pills benchmark. The brand appears in 21.62% of qualified AI observations but converts only 12.84% into valid recommendations, placing seventh of ten tracked brands. Its clearest win is a rank-one rate of 1.35% from a small base, and its clearest weakness is a 9.12% top-three rate that trails Hims, Ro, GoodRx Care, Lemonaid Health, and plushcare. The clearest opportunity is closing the gap between raw mention presence and recommendation conversion in the brand recommendation cluster.

Who This Report Is For

This report is written for BlueChew's growth, brand, and digital strategy leaders, and for category analysts tracking how telehealth ED treatment brands are surfaced and recommended across AI search and assistant platforms.

Report Card

Executive Summary

BlueChew is visible in the ED Treatment Pills category but is not converting that visibility into recommendation-stage strength. The October 2026 benchmark shows the brand at 21.62% raw mention presence, well behind Hims (92.57%), Ro (82.43%), and GoodRx Care (69.93%), and only modestly ahead of plushcare (30.74%) on presence while trailing plushcare on valid recommendation coverage (12.84% versus 22.97%).

The gap between presence and recommendation is the central finding. BlueChew is mentioned in roughly one in five qualified observations but receives valid recommendation credit in only 12.84% of them, a conversion ratio of roughly 59%. By comparison, Hims converts 92.57% presence into 60.81% recommendation coverage, and Ro converts 82.43% presence into 55.07% coverage. BlueChew is being named, but it is not being shortlisted at the same rate.

The strongest cluster for BlueChew is the only cluster with sufficient data, the brand recommendation cluster covering discovery and evaluation prompts. Within that cluster the brand records 9.12% top-three rate, 1.35% rank-one rate, and an average recommended rank of 2.86. The pricing and value and multi-brand comparison clusters carry no qualified observations in the October public series, so the brand's performance on cost and head-to-head prompts cannot be characterized from this dataset.

The strongest platform signal for BlueChew is Google AI Overviews, where the brand records 15 valid recommendations, a 12.71% valid recommendation coverage, and a 12.71% top-three rate. The weakest platform signal is ChatGPT and Perplexity, where BlueChew records zero valid recommendations in October despite appearing in the broader observation set on other surfaces.

Sentiment is not the problem. BlueChew records 48 positive mentions, 15 neutral mentions, and 1 negative mention, producing a net sentiment score of 0.7344. The brand is framed positively when it appears. The issue is that positive framing is not translating into shortlist placement at the rate the leading brands achieve.

The clearest platform gap is Copilot, where BlueChew records a 15.38% valid recommendation coverage but only an 11.54% top-three rate and a 0.00% rank-one rate, suggesting the brand is being listed as context rather than recommended as a leading option. The clearest cluster gap is the absence of qualified pricing and comparison observations, which limits what the public benchmark can say about BlueChew's competitive position on cost and direct matchups.

What BlueChew Is Winning

Questions This Section Answers

• Where is BlueChew already showing up as a leading recommendation on AI platforms?
• How does BlueChew's citation footprint compare to its recommendation-stage performance?

BlueChew's clearest evidence-backed win is its sentiment profile. With 48 positive mentions against 1 negative mention across 64 total mentions, the brand records a net sentiment score of 0.7344, which is positive and consistent with the category's framing norms. The single negative mention is the only negative classification recorded for the brand in October.

The brand also holds a narrow but meaningful rank-one pocket. BlueChew records 4 rank-one recommendations in October, a 1.35% rank-one rate, which places it ahead of K Health (0.00%) and Optum (0.00%) on first-position placements and level with Lemonaid Health at 1.35%, though Lemonaid's count of 4 also matches BlueChew's. This is a small base and should be read with caution, but it shows the brand can reach the first recommendation position on some prompts.

On platform, BlueChew's strongest signal is Google AI Overviews, where it records 15 valid recommendations, a 12.71% valid recommendation coverage, and a 12.71% top-three rate. Gemini is the second-strongest platform, with 9 valid recommendations and an 18.75% valid recommendation coverage. These two surfaces carry the majority of the brand's recommendation-stage presence.

The brand's presence in the citation environment is also notable. bluechew.com ranks fourth among all cited domains in October with 325 citations, a 5.00% share, and is cited across all six tracked platforms. That is a strong source-layer signal, even though it has not yet converted into recommendation-stage dominance.

Where BlueChew Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is BlueChew being mentioned in AI answers without being shortlisted?
• Which platforms and placement metrics represent BlueChew's biggest recommendation gaps?

The clearest gap is recommendation conversion. BlueChew appears in 21.62% of qualified observations but receives valid recommendation credit in only 12.84%. Hims, Ro, and GoodRx Care all convert presence into recommendation at materially higher rates, and plushcare, a brand with lower presence than BlueChew at 30.74%, converts at 22.97%, nearly double BlueChew's rate. The brand is being named without being chosen.

The second gap is top-three placement. BlueChew's 9.12% top-three rate places it behind Hims (48.65%), Ro (42.23%), GoodRx Care (35.47%), Lemonaid Health (17.91%), and plushcare (9.80%). The brand is closer to the middle of the table than to the leaders on shortlist inclusion, and the gap to plushcare is narrow enough that a small shift in either direction would change the ordering.

The third gap is platform coverage. BlueChew records zero valid recommendations on ChatGPT and zero on Perplexity in October. On ChatGPT the brand has no presence at all in the qualified set, and on Perplexity it records a single neutral mention with no recommendation credit. These are two of the six tracked surfaces, and the brand's absence from them limits its total recommendation footprint.

The fourth gap is rank-one conversion. BlueChew's 1.35% rank-one rate is well behind Hims (28.38%), GoodRx Care (15.88%), and Ro (9.80%). The brand reaches the first position rarely, and when it does, the base is small enough that individual placements carry outsized weight.

Biggest Opportunity

Questions This Section Answers

• What would change for BlueChew if its presence-to-recommendation conversion matched plushcare's rate?
• Which layers of the AI answer environment does BlueChew need to improve to be shortlisted rather than mentioned?

The single biggest opportunity for BlueChew is closing the presence-to-recommendation conversion gap in the brand recommendation cluster. The brand is already visible in roughly one in five qualified observations, and its sentiment is positive. The missing step is being shortlisted rather than mentioned. If BlueChew converted presence into valid recommendation at the rate plushcare achieves, its recommendation coverage would roughly double without any increase in raw mention presence. The work is therefore not about being found, it is about being chosen once found, which points to the owned answer layer, comparison framing, and citation-supported evidence that AI systems draw on when assembling a shortlist.

Competitive Landscape

Questions This Section Answers

• How does BlueChew's top-three and rank-one performance compare to Hims, Ro, and GoodRx Care?
• What does BlueChew's average recommended rank say about the quality of its placements when it does appear?

Hims and Ro hold the strongest recommendation-stage positions in the ED Treatment Pills category, with GoodRx Care close behind and rising. BlueChew sits in the middle of the tracked set, visible but not yet converting that visibility into shortlist placement at the rate the leaders achieve.

Average recommended rank covers rank-eligible recommendations only.

BlueChew's 9.12% top-three rate places it sixth of ten, narrowly behind plushcare and ahead of Rex MD. Its average recommended rank of 2.86 is stronger than plushcare's 3.67 and Lemonaid Health's 3.24, which indicates that when BlueChew does receive rank credit, it tends to land in a competitive position. The gap is in frequency of shortlist inclusion, not in the quality of placement when included.

AI Response Inconsistency Alerts

Questions This Section Answers

• What formulation and pricing conflicts did AI platforms produce about BlueChew?
• Which brand-owned pages appeared on one side of the conflicting AI answers?

Two critical or high-severity factual inconsistencies were detected for BlueChew across three AI platforms: Copilot, Google AI Mode, and Google AI Overviews.

The first conflict concerns the active ingredients in BlueChew Gold. When asked "What is similar to BlueChew gold?", Google AI Mode stated that BlueChew Gold combines sildenafil, tadalafil, apomorphine, and oxytocin, citing bluechew.com/gold, innerbody.com, and a BlueChew brand story page. Copilot, answering the same question, stated that BlueChew Gold combines sildenafil, tadalafil, vardenafil, and apomorphine, citing a BlueChew comparison page, nerdbible.com, and menshealthinsider.co. The two answers cannot both accurately describe the same formulation: one includes oxytocin but not vardenafil, the other includes vardenafil but not oxytocin. Flagged source pages supporting the oxytocin formulation include bluechew.com/our-stories/is-bluechew-gold-stronger-than-viagra-or-cialis, bluechew.com/our-stories/bluechew-gold-date-night, and bluechew.com/our-stories/bluechew-gold-prescribed-online.

The second conflict concerns the price of a 6-pack of BlueChew. When asked "How much is a 6 pack of BlueChew?", Google AI Overviews stated that the BlueChew Gold Plan, described as a 4-in-1 premium compound, costs between $79 and $139 per month for a 6-pack, citing bluechew.com/our-stories/bluechew-cost-what-you-need-to-know, bluechew.com/gold/plan, and healthline.com. Copilot stated that a 6-pack of BlueChew typically costs about $25 per month, with higher quantities ranging from $35 to $130 per month, citing medicalnewstoday.com, a BlueChew blog page, and choosingtherapy.com. The premium 6-pack price ranges described by the two platforms are incompatible. A flagged source page supporting the higher range is bluechew.com/our-stories/bluechew-cost-what-you-need-to-know, which states that Gold starts around $75 per month for 6 doses and rises to $269 per month for 24 doses.

Both conflicts are factual and high-confidence, and both involve brand-owned pages appearing on one side of the disagreement. This pattern suggests that AI systems are synthesizing from a mix of brand-owned and third-party sources that do not agree on formulation or pricing details.

Prompt Evidence

Google AI Mode / Brand Recommendation Prompt: "What is similar to BlueChew gold?" Result: Google AI Mode recommended BlueChew Gold and described its formulation, but listed oxytocin as an active ingredient, conflicting with Copilot's answer to the same question.

Copilot / Brand Recommendation Prompt: "What is similar to BlueChew gold?" Result: Copilot recommended BlueChew Gold but described a different active ingredient set than Google AI Mode, and cited third-party comparison pages alongside a brand-owned page.

Google AI Overviews / Brand Recommendation Prompt: "How much is a 6 pack of BlueChew?" Result: Google AI Overviews surfaced a premium 6-pack price range of $79 to $139 per month, while Copilot surfaced a much lower typical price, producing a pricing conflict across platforms.

Gemini / Brand Recommendation Prompt: "What generic Viagra is best?" Result: Gemini surfaced BlueChew among recommended options, contributing to the brand's strongest platform-level recommendation coverage at 18.75%.

What CiteWorks Studio Would Do Next

Phase 1: AI Visibility Market Discovery Audit Map BlueChew's prompt-level presence, recommendation, and citation patterns across all six tracked platforms to identify exactly which prompts produce mentions without recommendations.

Phase 2: Recommendation Readiness Plan Prioritize the prompt themes where BlueChew is named but not shortlisted, and define the framing, comparison, and evidence changes needed to convert presence into recommendation credit.

Phase 3: Owned Answer Layer Buildout Strengthen BlueChew's owned pages so that formulation, pricing, and comparison content is consistent, extractable, and easy for AI systems to synthesize without contradiction.

Phase 4: Citation / Authority Layer Development Expand and align the third-party source footprint so that external pages reinforce the same formulation and pricing facts the brand publishes, reducing the risk of conflicting AI answers.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track BlueChew's presence, valid recommendation coverage, top-three rate, rank-one rate, and sentiment month over month, with platform-level breakouts to catch gaps early.

Why This Matters

AI presence alone is not enough. BlueChew is already visible in roughly one in five qualified AI observations, and its sentiment is positive, but it is not being shortlisted at the rate the category leaders achieve. In a category where buyers increasingly form their shortlist inside an AI answer, being mentioned without being recommended is a commercial gap, not a branding win.

The next move is targeted correction of the prompt, page, and citation layers. The brand needs consistent formulation and pricing facts across owned and third-party sources, stronger comparison and value framing on the prompts where it is already visible, and a citation footprint that reinforces rather than contradicts its own claims. That is the path from reference to recommendation.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For BlueChew in October 2026: (48 × 1 + 15 × 0 + 1 × -1) / 64 = 47 / 64 = 0.7344.

This matters because unclassified mention counts are misleading. A brand can appear frequently in AI answers without ever being recommended, and a raw mention count treats a positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention as if they were equal. They are not. Share of voice is a diagnostic metric, not a business KPI. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because it separates framing quality from recommendation strength and shows whether the brand is being described favorably, neutrally, or with caution when it appears.

Sentiment by Platform

Questions This Section Answers

• Which platforms show the strongest positive sentiment toward BlueChew, and which show the weakest?
• How do Copilot and Perplexity sentiment patterns differ from Google AI Overviews and Gemini?

Methodology

1. This report is a benchmark-based analysis of BlueChew's AI visibility and recommendation performance in the ED Treatment Pills category for October 2026. It is not a client implementation case study and does not imply that any remediation work caused the observed outcomes.
2. The reporting window is October 2026, with July 2026 as the baseline month for movement comparisons where the source data supports them.
3. Six AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode. All six registered qualified observations in October.
4. The October run began with 800 prompt-surface observations and 658 unique questions. Of those, 547 were relevant to the category, 253 were irrelevant, and 296 qualified observations formed the public denominator for brand-level percentages.
5. The competitor universe for October 2026 contained ten tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, plushcare, BlueChew, Rex MD, Blink Health, K Health, and Optum.
6. Three public high-intent clusters were in scope: brand recommendation (discovery and evaluation), pricing and value, and multi-brand comparison. Only the brand recommendation cluster carried qualified observations in October.
7. Stage 0 extraction retained the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources for each prompt-level observation.
8. A mention is counted when BlueChew appears in a qualified AI response, regardless of whether it is recommended. A valid recommendation is counted only when the dataset explicitly marks the brand as a valid recommendation with rank credit.
9. Top-three rate, rank-one rate, and average recommended rank are calculated against the 296 qualified observations. Average recommended rank covers rank-eligible recommendations only.
10. Sentiment is classified as positive, neutral, or negative at the mention level. Net sentiment score is the balance of positive versus negative mentions on a scale from 0 to 1.
11. The benchmark records change; it does not establish why change occurred. Source presence in AI responses is evidence about the information environment and is not automatically proof of causation.
12. Limitations: the public series does not contain qualified pricing and value or multi-brand comparison observations, so BlueChew's performance on cost and head-to-head prompts cannot be characterized from this dataset. Small-count movements for brands with few valid recommendations carry limited weight. The benchmark does not measure market share, sales, revenue attribution, organic-search ranking, or social media sentiment.

See How AI Is Recommending Your Brand

The public benchmark shows where BlueChew is visible and where it is being passed over. A company-level AI visibility audit maps the prompt, platform, competitor, ranking, sentiment, and citation patterns behind those numbers into a prioritized plan for closing the recommendation gap.